ReviewJournal of personalized medicine2022
Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Personalized medicine as a novel therapeutic approach for autoimmune diseases: new insights and future prospects.Osong public health and research perspectives · 2026Article
- Molecular Pharmacology at the Crossroads of Precision Medicine.Current issues in molecular biology · 2025Article
- 3D Printed Microfluidic Chromatographic Column for Fast Downstream Processing Development.Biotechnology journal · 2025Article
- Multiple Exposures of Plasma to Nanoparticles: A Novel Tool to Personalize Biomolecular Coronas and Fractionate Fluids.Analytical chemistry · 2025Article
- Recent Progress in PDMS-Based Microfluidics Toward Integrated Organ-on-a-Chip Biosensors and Personalized Medicine.Biosensors · 2025Review
- A Review of the Applications, Benefits, and Challenges of Generative AI for Sustainable Toxicology.Current research in toxicology · 2025Review
- Clinical exome sequencing identifies novel gene variants associated with ischemic stroke in the Saudi Tabuk population.Frontiers in human neuroscience · 2025Article
- Bibliometric Analysis of Exosome Research in Spinal Cord Injury (2000-May 2024). Trends, Collaborations, and Emerging Insights.Drug design, development and therapy · 2025Article
- Trends analysis and future study of the pharmaceutical industry field: a scoping review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Emerging Strategies in Drug Development and Clinical Care in the Era of Personalized and Precision Medicine.Pharmaceutics · 2024Article
- The Roadmap toward Personalized Medicine: Challenges and Opportunities.Journal of personalized medicine · 2024Article
- Promoting advanced medical services in the framework of 3PM-a proof-of-concept by the "Centro" Region of Portugal.The EPMA journal · 2024Review
- Regulated Pricing Decisions and Diagnostic Test Choices in Personalized Medicine: Navigating the Implications Within Legal Frameworks.Risk management and healthcare policy · 2024Article
- Machine Learning-Assisted Short-Wave InfraRed (SWIR) Techniques for Biomedical Applications: Towards Personalized Medicine.Journal of personalized medicine · 2023Review
- [Evidence-based versus expertise-based medicine in orthopedic and trauma surgery : There is nothing more practical than a good theory].Orthopadie (Heidelberg, Germany) · 2023Review
- Personalized Medicine in Ophthalmic Diseases: Challenges and Opportunities.Journal of personalized medicine · 2023Article
- A supramolecular cucurbit[8]uril-based rotaxane chemosensor for the optical tryptophan detection in human serum and urine.Nature communications · 2023Article
- Recent Advances and Future Challenges in the Field of Digestive Diseases.Medicina (Kaunas, Lithuania) · 2023Article
- Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer.Frontiers in pharmacology · 2023Article
- Feasibility of Precision Medicine in Hypertension Management-Scope and Technological Aspects.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, with the advancement of next-generation sequencing (NGS) technology, gene panel tests have been approved in the field of cancer diseases, and approaches to prescribe optimal molecular target drugs to patients are being developed. In the field of rare diseases, whole-genome and whole-exome analysis has been used to identify the causative genes of undiagnosed diseases and to diagnose patients' diseases, and further progress in personalized medicine is expected. In order to promote personalized medicine in the future, we investigated the current status and progress of personalized medicine in disease areas other than cancer and rare diseases, where personalized medicine is most advanced. We selected rheumatoid arthritis and psoriasis as the inflammatory disease, in addition to Alzheimer's disease. These diseases have high unmet needs for personalized medicine from the viewpoints of disease mechanisms, diagnostic biomarkers, therapeutic drugs with diagnostic markers and treatment satisfaction. In rheumatoid arthritis and psoriasis, there are many therapeutic options; however, diagnostic methods have not been developed to select the best treatment for each patient. In addition, there are few effective therapeutic agents in Alzheimer's disease, although clinical trials of many candidate drugs have been conducted. In rheumatoid arthritis and psoriasis, further elucidation of the disease mechanism is desired to enable the selection of appropriate therapeutic agents according to the patient profile. In the case of Alzheimer's disease, progress in preventive medicine is desired through the establishment of an early diagnosis method as well as the research and development of innovative therapeutic agents. To this end, we hope for further research and development of diagnostic markers and new drugs through progress in comprehensive data analysis such as comprehensive genomic and transcriptomic information. Furthermore, new types of markers such as miRNAs and the gut microbiome are desired to be utilized in clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.